To examine the short-term effects of a lipase inhibitor (Orlistat) on physiological and behavioural measures of appetite in response to a high-fat meal. DESIGN: Randomised, single blind, placebo-controlled, crossover trial. SUBJECTS: A total of 19 healthy nonobese male subjects. PROCEDURES: After an overnight fast, subjects ingested a test meal of 2940 kJ (60% fat, 30% CHO, 10% protein) with Orlistat (120 mg) or a placebo, separated by 2 weeks. Appetite, as assessed by a standard line scale, and plasma cholecystokinin (CCK) concentrations were measured prior to and every hour after the test meal for 4 h. Thereafter, subjects ingested a quantified, but self-selected portion of a standardised lunch (15% protein, 37% fat and 45% CHO), before completing a final line scale questionnaire. RESULTS: The CCK response to the test meal was negatively correlated with BMI in both the Orlistat and placebo trials (R ¼ À0.69 and À0.65, Po0.01). Orlistat administration did not significantly alter the CCK response to the test meal (6.3073.27 vs 7.3673.94 pM min, for Orlistat and placebo, P ¼ 0.193). Similarly, the line scale measures of appetite and subsequent intake (5207205 vs 5547197 g, P ¼ 0.48) were not different between the trials. CONCLUSION: Orlistat administration did not alter short-term physiological or behavioural measures of satiety in response to a high-fat meal in healthy, nonobese subjects. The CCK response to a test meal may be partly determined by BMI.
Introduction
Satiety refers to the reduction of hunger and represents the interplay of psychological, physiological and metabolic events.
1 Cholecystokinin (CCK) is one of the most established gastrointestinal peptides that is implicated in the suppression of food intake or appetite control. 2 When CCK-8 is infused, resulting in plasma CCK concentrations similar to the postprandial state, there is a subsequent reduction in caloric intake, 3, 4 decreased feelings of hunger and increased fullness 4 in normal weight persons. Conversely, loxiglumide, a specific CCK-A receptor antagonist, stimulates calorie intake and feelings of hunger, and delays fullness. [4] [5] [6] [7] These studies therefore provide evidence for a physiological role of CCK, acting via peripheral CCK-A receptors, in mediating satiation signals that reduce meal size and energy intake. Dietary fat is a potent secretagogue for CCK release from the endocrine cells of the duodenum and jejunum. 8 However, CCK is only released in response to adequate triglyceride hydrolysis by pancreatic lipase that increases intraduodenal long-chain FFA (4C10) concentrations. 7, [9] [10] [11] [12] Both Borovicka et al 11 and Schwizer et al 12 demonstrated that intragastric administration of Orlistat with a stable emulsion of triglycerides (10% Intralipid), which reduced lipolysis by 75%, inhibited plasma CCK release. When administered intraduodenally, Orlistat also attenuated the CCK response to a triglyceride emulsion. 9, 10 These studies therefore suggest that intragastric and intraduodenal administration of Orlistat attenuates CCK release, via its inhibitory effects on lipolysis. This attenuation may in turn modify CCK's functional capacity and its downstream effects on satiety, as observed by Matzinger et al, 7 who demonstrated that intraduodenal administration of Orlistat inhibited CCK release and attenuated the reduction in food intake associated with intraduodenal fat perfusion. To our knowledge, there are no studies that have examined the effects of oral lipase inhibitor administration, as opposed to intragastric or intraduodenal, on plasma CCK release and its consequent effects on behavioural satiety and hunger. Therefore, the aims of the present study were to examine the effects of oral administration of Orlistat on plasma CCK release and measures of behavioural satiety and hunger in response to a high-fat meal.
Methods
Subject selection A total of 19 healthy nonobese male subjects participated in this randomised, single-blind, placebo-controlled crossover study, which was approved by the Research and Ethics Committee of the Faculty of Medicine of the University of Cape Town. Entry criteria included: (1) a body mass index (BMI) of less than 30 kg/m 2 ; (2) the absence of known metabolic conditions, which may adversely affect intermediary metabolism (eg diabetes, thyroid hormone disorder, hyperlipidemia, etc); (3) no medications for chonic conditions such as high blood pressure (eg b-adrenergic receptor antagonists) or stimulants for conditions such as asthma (eg b-adrenergic receptor agonists). The risks were carefully explained to the subjects and their informed consent was obtained in writing before participation in the trial. The mean age, weight, height and BMI of the subjects were 2171.6 y, 74.079.4 kg, 1.7670.08 m and 23.772.2 kg/m 2 , respectively. The BMI of the subjects ranged from 19.6 to 27.7 kg/m 2 . Healthy nonobese subjects were included in the trial to allow for comparisons with studies that examined the effects of intragastric and intraduodenal, as opposed to oral, administration of Orlistat on physiological and behavioural satiety in healthy subjects. 7, [9] [10] [11] [12] Obese subjects were also excluded from the trial to reduce any possible confounding effects of obesity on physiological and behavioural measures of appetite.
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Experimental trial
The subjects completed two randomised trials separated by 2 weeks, during which they ingested a test meal with Orlistat (120 mg) or placebo (2 g flour). When taken with a fatcontaining meal, this dose of Orlistat results in faecal excretion of dietary fat from a normal range of 1-5% up to 18-32%. 15, 16 Satiety and hunger were measured and blood samples drawn prior to and every hour after the test meal for 4 h for the determination of plasma CCK levels. Subjects then ingested a quantified, but self-selected portion of a standardised lunch after which hunger and satiety were measured again. Subjects remained in a resting state and were permitted to drink 250 ml of water throughout the experimental trial. Blood sampling. On each trial day, the subjects reported to the laboratory after a 10-12 h overnight fast. A flexible 20-gauge cannula for the withdrawal of blood samples was inserted into the subjects' antecubital vein and kept patent by flushing with B1 ml of 0.9% sterile saline. Fasting blood samples (10 ml) were drawn for the determination of plasma glucose, insulin and CCK concentrations. Thereafter, samples (5 ml) were drawn every hour for 4 h after the test meal for the subsequent determination of plasma CCK concentrations. Samples for glucose estimation were placed in tubes containing potassium oxalate and sodium fluoride. Samples for plasma CCK and insulin estimations were collected in tubes containing lithium heparin. All samples were kept on ice until centrifuged at 3000 rpm for 10 min at 41C. Samples for the determination of plasma insulin and glucose concentrations were stored at À201C, and samples for the determination of plasma CCK concentrations were stored at À801C for subsequent analyses.
Plasma glucose concentrations were determined using the glucose oxidase method (Glucose Analyzer 2, Beckman Instruments, Fullerton, CA, USA). Plasma insulin concentrations were determined by nonspecific insulin radioimmunoassay (Count-A-Coat Insulin; Diagnostic Products, Los Angeles, CA, USA), with an intra-and inter-assay coefficient of variation of 4.5 and 6.6%, respectively. Plasma CCK concentrations were measured by a commercially available sensitive radioimmunoassay (Euro-Diagnostica, Malmoe, Sweden) using an antiserum raised against sulphated CCK-8 N-terminally conjugated to bovine albumin. The antiserum, which recognises the sulphated tyrosine residue of CCK-8, has no relevant crossreactivity with sulphated gastrin. Plasma samples were extracted with ethanol. The detection limit of the assay was 0.6 pM/l plasma using CCK-8 as a standard. Inter-and intra-assay variabilities were 13.7 and 5.5%, respectively. Matched patient samples were measured in the same assay.
Satiety and hunger questionnaire. Ratings of motivation to eat (hunger, satiety, fullness and prospective consumption) were also assessed prior to the test meal, every hour for 4 h after the test meal and immediately after lunch, using a 100 mm line scale. 17 Subjects were required to mark their appetite sensation on the line. Each sensation was assessed with a separate line scale anchored with the opposing
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Post-test meal (lunch).
At 4 h after the test meal and immediately after the last blood sample was drawn, subjects ate a standardised lunch of macaroni cheese (15% protein, 37% fat, 45% carbohydrate), which was of a similar composition to a typical Western South African diet. 18 This meal was cooked in a single batch, divided into storage containers and frozen for subsequent use during each experimental trial. The night before each trial, one batch was placed in the refrigerator to defrost. Subjects consumed (ad libitum) self-selected quantity of the lunch, according to their appetite. The quantity of food consumed, and hence energy intake, was determined by weighing the plate of food prior to and after completion of the meal and measuring plate wastage. Once the subjects felt they had eaten sufficiently, they completed a final line scale for appetite ratings. Subjects were contacted telephonically the day after each trial to enquire about any side effects as a result of the trial.
Dietary analysis. The subjects were asked to keep their diets constant in the 3 days prior to the two experimental trials. This was assessed by the subjects completing a 3-day dietary record, which was analysed with the Food Finder program (MRC, Tygerberg, South Africa).
Statistical analyses
Sample size determination (80% power, a-level 0.05), conducted prior to the commencement of the study, found that less than 19 subjects were required to show differences in mean plasma CCK concentrations and energy intakes similar in magnitude to those demonstrated in response to intragastric and intraduodenal Orlistat administration, respectively. 7, 11 Results are expressed as means7s.d. t-Tests for dependent samples were used to examine differences in dietary intake during the 3 days prior to the experimental trials, quantity of lunch consumed, fasting blood concentrations and incremental area under the curve for plasma CCK concentrations and appetite scores. Repeated-measures analyses of variance (ANOVA) were used to examine differences between trials over time for plasma CCK concentrations and appetite scores. A Tukey's HSD post hoc test was performed to locate differences over time. An alpha level of r0.05 was considered statistically significant.
Results
Satiety, hunger and post-test intake
The effects of Orlistat or placebo administration on ratings of appetite in response to a high-fat meal are presented in Figure 1 . Orlistat did not alter the ratings of hunger, satiety, prospective consumption or fullness, when examining Oral Orlistat administration and satiety JH Goedecke et al changes over time (Figure 1 ) or the area under the curve (Table 1) , in response to the high-fat meal. Similarly, there were no differences in post-test meal intake between the Orlistat and placebo trials, with a mean difference of only 347199 g between trials (P ¼ 0.48). The mean post-test meal intake for each trial is presented in Table 2 .
Blood samples
The plasma CCK response to the test meal displayed a similar profile to the line scales for satiety and fullness, increasing significantly in the first hour after the high-fat test meal (Po0.001), and then decreasing significantly (Po0.001) and returning to near baseline levels after 4 h (Figure 2) . However, the area under the plasma CCK curves did not correlate with the area under the appetite response curves for the Orlistat and placebo trials (R ¼ À0.11, P ¼ 0.65 and R ¼ À0. 16 , P ¼ 0.53 for satiety, respectively).
There was also no significant difference in the plasma CCK response to the high-fat test meal with Orlistat compared to placebo administration (P ¼ 0.334 for trial Â time interaction, Figure 2 ). The areas under the plasma CCK curve for the Orlistat vs placebo trials were 6.3073.27 vs 7.367 3.94 pM min, respectively (P ¼ 0.193). The CCK response to the test meal was extremely variable, with the peak plasma CCK concentrations ranging from 0.7 to 7.0 pmol/l with Orlistat administration and from 0.7 to 8.4 pmol/l with placebo administration.
The variability in plasma CCK response to the high-fat test meal may be explained, in part, by the variability in body fatness. BMI correlated negatively with area under the plasma CCK curve for both the Orlistat and placebo trials (R ¼ À0.690, P ¼ 0.001 and R ¼ À0.649, P ¼ 0.003, respectively, Figure 3 ). Body weight, however, did not correlate with the area under the plasma CCK curve in the Orlistat and placebo trials (r ¼ À0.322, P ¼ 0.178 and r ¼ À0.414, P ¼ 0.078, respectively). When covarying for BMI, the plasma CCK response to the high-fat test meal was still not significantly different between the Orlistat and placebo trials (P ¼ 0.261 for trial Â time interaction).
There were no differences in fasting plasma glucose (4.3370.27 vs 4.3070.19 mmol/l, P ¼ 0.622) and insulin (5.4772.28 vs 4.5472.17 mU/ml, P ¼ 0.255) concentrations between the Orlistat and placebo trials, respectively.
Side effects of Orlistat and placebo administration
Four of the subjects experienced gastrointestinal side effects, reported after the trial, as a result of Orlistat administration. Two of the subjects reported increased flatulence, another subject experienced cramping and only one subject experienced severe side effects including cramping and diarrhoea. No subjects reported gastrointestinal side effects with placebo administration.
Dietary analysis
Although the trials were randomised, there was a significant difference in dietary intake in the 3 days preceding the experimental trials (Table 3 ). The subjects consumed more energy (P ¼ 0.039) and, as a result, more fat (P ¼ 0.010) and carbohydrate (P ¼ 0.036), in the 3 days prior to the Orlistat trial compared to the placebo trial. The percentage contribution of fat and protein to total energy intake also increased in the days preceding the Orlistat compared to the placebo trial. However, when covarying for total energy, dietary fat and carbohydrate intake and percentage fat and protein intake, the plasma CCK response to Orlistat or placebo administration with a high-fat test meal did not change. Oral Orlistat administration and satiety JH Goedecke et al
Discussion
The major findings of this study were that oral administration of a lipase inhibitor (Orlistat) did not significantly reduce plasma CCK release or modify short-term subjective feelings of hunger or satiety in response to a high-fat test meal in healthy male subjects. To our knowledge, this is the first study to examine the effects of oral administration of Orlistat on CCK release in response to a test meal. Previous studies have only examined the effects of intragastric or intraduodenal administration of a lipase inhibitor (Orlistat), and have found that when administered with 30-55 g of stable triglyceride emulsions, CCK release is inhibited. [9] [10] [11] [12] Hildebrand et al 9 demonstrated that intraduodenal perfusion of a 30 g olive oil solution resulted in a threefold increase in plasma CCK concentrations from basal levels during the first postprandial hour that remained elevated for the remaining 4 h. In contrast, plasma CCK concentrations did not increase significantly during the experiment when Orlistat was administered. 9 Thus adequate digestion of dietary triglycerides by pancreatic lipase to produce FFAs is necessary for the release of endogenous CCK in response to food intake, particularly in the immediate postprandial period. As Orlistat inhibits lipolysis 9 and therefore reduces the appearance of FFAs in the small intestine, the release of CCK would be inhibited. Yet in this study, although the high-fat test meal (47 g fat (60% of energy), 17.5 g protein, 53 g carbohydrate) resulted in a rise in plasma CCK concentrations to levels similar to that elicited by intragastric and intraduodenal administration of similar quantities of lipid emulsion (B3-4 pmol/ l), 10, 12 oral administration of Orlistat did not inhibit CCK release at the time points measured. These findings therefore suggest that oral administration of Orlistat is associated with less effective inhibition of intestinal lipase activity than that seen with intragastric and intraduodenal administration. The extent of postprandial inhibition of gastric and pancreatic lipase activity depends mainly on the effective distribution of the extremely hydrophobic Orlistat with the test meal, 12 such that hydrolysis of triglycerides is prevented.
The studies that used intragastric and intraduodenal administration of Orlistat took special care to make stable emulsions with the test meals, [10] [11] [12] or used a lipophilic carrier such as an egg-oil emulsion 9 to insure homogenous distribution of Orlistat in the test meal. In these studies, administration of Orlistat with a liquid meal almost completely inhibited gastric and pancreatic lipase activity (B77%), 19 reduced FFA concentrations in the small intestine to less than 5% of control and suppressed plasma CCK levels by 50-77%. 9, 11, 12 We are unable to comment on the magnitude of effect of Orlistat taken orally in combination with a test meal in this study, as we did not directly measure lipase activity, nor did we measure faecal fat content, as an indirect measure of lipase activity. Oral Orlistat administration and satiety JH Goedecke et al infused into the duodenum) are required to stimulate CCK release. 9 The lack of effect of oral Orlistat administration on CCK levels in our study may be explained by a number of additional factors. Firstly, the protein content of the meal (17.5 g) could act as a CCK secretagogue, independent of triglyceride hydrolysis. 8 Secondly, there was a large variability in the CCK response in both trials. We found a 10-fold difference in the peak plasma CCK concentrations in response to the high-fat test meal in both trials in the apparently healthy male subjects. The variability in the CCK response to the test meal was largely explained by body fatness (Figure 3 ), but not by body weight. The observation that the CCK response to the high-fat test meal correlated negatively with BMI, suggesting that those subjects with the highest BMI had the lowest CCK response to the high-fat test meal, has not been previously described. Moreover, this study provides physiological support for the behavioural research of Rolls et al, 13 who demonstrated that overweight or obese subjects display some insensitivity to the satiating effects of fat.
Irrespective of body fatness, oral Orlistat administration did not reduce the CCK response to the test meal, suggesting that the CCK-dependent regulatory functions remained operational. Researchers have demonstrated that CCK-8 infusions, leading to physiological postprandial plasma CCK concentrations, reduce subsequent caloric intake, 3, 4 decrease feelings of hunger and increase fullness. 4 Conversely, loxiglumide, a specific CCK-A receptor antagonist, stimulates calorie intake and feelings of hunger, and delays fullness. [4] [5] [6] [7] However, as already discussed, hydrolysis of dietary triglycerides by pancreatic lipase is necessary for the release and, presumably, the function of endogenous CCK. Indeed, Matzinger et al 7 demonstrated that intraduodenal administration of fat reduced the amount of food eaten at a subsequent meal (60 min after starting the perfusion) by 20%, corresponding to a 23% reduction in calorie intake. Orlistat administration with the infusate reversed this effect. As oral Orlistat administration did not alter CCK release in the present study, changes in behavioural measures of appetite were not expected and not observed. We found that line scale measures of hunger, satiety and prospective intake did not change in response to oral Orlistat administration (Table 1 and Figure 1) . Food intake at the post-test meal, ingested 4 h after the test meal, was also remarkably similar between trials (Table 2) , with a difference in food intake of only B30 g (44 kcal). It may, however, be difficult to demonstrate any clear relationship between hunger and manipulations of energy intake in the laboratory, as there is strong evidence that a large component of motivation to eat is entrained. 20 Therefore, small manipulations of energy balance may not be large enough to overcome these entrained effects, suggesting that the subjectively rated motivation to eat is not an inevitable outcome of underlying physiological processes. 20 The palatability of a meal may also override, to a certain extent, the inhibitory signals associated with preload ingestion. 21 Although dietary control is preferred in a study of this nature, it is unlikely that the small differences in energy or fat intake in the 3 days preceding the experimental trials altered the findings of this study. This is supported by a recent validation study in which the reliability of the appetite rating scores was not influenced by prior diet standardisation. 22 Moreover, Silberbauer et al 23 found that the fat level of the habitual diet, recorded for 7 days prior to the experimental trial, did not alter hunger ratings and subsequent lunch intake.
In conclusion, oral administration of a lipase inhibitor (Orlistat) did not attenuate the plasma CCK response to a high-fat test meal and, accordingly, did not alter behavioural satiety in healthy, nonobese subjects. The CCK response to the high-fat test meal was significantly negatively correlated with BMI.
